Valuation dashboard for AC Immune S.A. (ACIU) with P/E N/A, P/B 6.42, EV/EBITDA -5.05 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically.
Analysis Summary
AC Immune S.A. reported revenue of $3.6M in the most recent fiscal year, growing at a 5-year CAGR of -25.4%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -252.3%, net margin -246.5%.
At the current price of $2.65, ACIU has negative trailing earnings (P/E not meaningful) and an ROE of -99.17%. Market capitalisation stands at $270M.
Balance sheet quality for ACIU: current ratio of 1.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 6.42 |
| EV / EBITDA | -5.05 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.03 |
| vs Current Price | -101.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACIU | AC Immune S.A. | $270M | 6.42 | -99.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.65 |
| Market Cap | $270M |
| Exchange | NASDAQ |
| Country | CH |
Profitability
| Return on Equity | -99.17% |
| Return on Invested Capital | -86.61% |
| Return on Assets | -28.70% |
| Gross Margin | 100.00% |
| Operating Margin | -252.25% |
| Net Margin | -246.49% |
Related companies: ALDX · AMRN · ANNX · ANRO · CLLS · CTNM · DRTS
Explore sector: Healthcare · Biotechnology
More sections of ACIU: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks